Published in Br J Haematol on May 01, 2001
Complement receptor Mac-1 is an adaptor for NB1 (CD177)-mediated PR3-ANCA neutrophil activation. J Biol Chem (2010) 1.07
Graft-versus-leukemia reactions after bone marrow transplantation. Blood (1990) 7.11
A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med (2013) 6.67
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia (2009) 6.29
Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood (1995) 5.34
The molecular biology of chronic myeloid leukemia. Blood (2000) 5.22
A simple, easy, and inexpensive method for monitoring ETCO2 through nasal cannulae. Anesthesiology (1987) 4.19
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia (2008) 3.58
Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol (1997) 2.79
The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib. Leukemia (2006) 2.49
Interleukin-1 beta-modulated gene expression in immortalized human chondrocytes. J Clin Invest (1994) 2.42
T-cell depletion of HLA-identical transplants in leukemia. Blood (1991) 2.25
Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br J Haematol (1997) 2.14
Heredopathia atactica polyneuritiformis: Refsum's disease. Acta Neurol Scand (1985) 2.03
The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood (1997) 1.96
Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood (2000) 1.94
Health and functional status of long-term survivors of bone marrow transplantation. EBMT Working Party on Late Effects and EULEP Study Group on Late Effects. European Group for Blood and Marrow Transplantation. Ann Intern Med (1997) 1.93
Long-term expression of human adenosine deaminase in mice transplanted with retrovirus-infected hematopoietic stem cells. Proc Natl Acad Sci U S A (1989) 1.91
An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders. Leukemia (1994) 1.88
P190BCR-ABL chronic myeloid leukaemia: the missing link with chronic myelomonocytic leukaemia? Leukemia (1994) 1.88
A novel fusion between MOZ and the nuclear receptor coactivator TIF2 in acute myeloid leukemia. Blood (1998) 1.87
Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood (2000) 1.84
Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa. Leukemia (2003) 1.84
A new myeloproliferative disorder associated with chromosomal translocations involving 8p11: a review. Leukemia (1995) 1.81
Pregnancy outcomes after peripheral blood or bone marrow transplantation: a retrospective survey. Lancet (2001) 1.76
Strongyloidiasis pre and post autologous peripheral blood stem cell transplantation. Bone Marrow Transplant (2003) 1.71
The platelet count and mean platelet volume. Br J Haematol (1981) 1.70
hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia. Leukemia (2010) 1.67
Prolymphocytic leukaemia. Br J Haematol (1974) 1.66
Appropriate controls for reverse transcription polymerase chain reaction (RT-PCR) Br J Haematol (1994) 1.60
Bone-marrow transplantation for leukaemia. Lancet (1995) 1.60
Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia. Nature (1987) 1.59
Malignant neoplasms in long-term survivors of bone marrow transplantation. Late Effects Working Party of the European Cooperative Group for Blood and Marrow Transplantation and the European Late Effect Project Group. Ann Intern Med (1999) 1.59
Collection, cryopreservation and subsequent viability of haemopoietic stem cells intended for treatment of chronic granulocytic leukaemia in blast-cell transformation. Br J Haematol (1978) 1.55
Response to donor lymphocyte infusions for chronic myeloid leukemia is dose-dependent: the importance of escalating the cell dose to maximize therapeutic efficacy. Leukemia (2007) 1.53
HLA-DR4 is associated with a diminished risk of the development of chronic myeloid leukemia (CML). Chronic Leukemia Working Party of the European Blood and Marrow Transplant Registry. Leukemia (2000) 1.49
1,25-dihydroxyvitamin D3 inhibits proliferation of human promyelocytic leukaemia (HL60) cells and induces monocyte-macrophage differentiation in HL60 and normal human bone marrow cells. Leuk Res (1983) 1.48
Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16-year period. Br J Haematol (1997) 1.48
Co-trimoxazole for prevention of infection in acute leukaemia. Lancet (1978) 1.47
The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins. Blood (2001) 1.47
Role of allo-SCT for CML in 2010. Bone Marrow Transplant (2010) 1.46
Atrazine disrupts the hypothalamic control of pituitary-ovarian function. Toxicol Sci (2000) 1.46
A new controlled-rate cooling apparatus for freezing hematopoietic cells for storage at -196 degrees C. Cryobiology (1973) 1.45
Outbreak of gastroenteritis due to Salmonella virchow in a maternity hospital. Br Med J (1969) 1.44
Allogeneic bone marrow transplantation for primary myelofibrosis. Br J Haematol (1989) 1.43
Variable numbers of BCR-ABL transcripts persist in CML patients who achieve complete cytogenetic remission with interferon-alpha. Br J Haematol (1995) 1.43
An account of 335 cases of megaloblastic anaemia of pregnancy and the puerperium. J Clin Pathol (1966) 1.42
Late onset immune pancytopenia following bone marrow transplantation. Br J Haematol (1991) 1.42
Vasculitic neuropathy in association with chronic graft-versus-host disease. J Neurol Sci (1999) 1.41
Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med (2001) 1.39
A comparison of the sensitivity of blood and bone marrow for the detection of minimal residual disease in chronic myeloid leukaemia. Br J Haematol (1994) 1.39
Bone marrow transplantation in Europe: major geographical differences. The European Group for Bone Marrow Transplantation [EBMT]. J Intern Med (1993) 1.39
Busulfan alone as cytoreduction before autografting for chronic myelogenous leukemia. Blood (1998) 1.39
Computerized patient anesthesia records: less time and better quality than manually produced anesthesia records. J Clin Anesth (1993) 1.39
Septicaemia caused by viridans streptococci in neutropenic patients with leukaemia. Lancet (1984) 1.38
The effect of cytomegalovirus on hemopoiesis: in vitro evidence for selective infection of marrow stromal cells. Exp Hematol (1989) 1.35
Granulocyte transfusions in treatment of infections in patients with acute leukaemia and aplastic anaemia. Lancet (1975) 1.33
Bone marrow transplantation for patients with chronic myeloid leukemia. N Engl J Med (1986) 1.33
Oral ketoconazole and amphotericin B for the prevention of yeast colonization in patients with acute leukaemia. J Hosp Infect (1984) 1.31
Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood (1993) 1.30
Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant (1998) 1.30
The association of age with the presentation and outcome of tuberculosis: a five-year survey. Age Ageing (1993) 1.30
Diverging effects of HLA-DPB1 matching status on outcome following unrelated donor transplantation depending on disease stage and the degree of matching for other HLA alleles. Leukemia (2009) 1.29
The immunoglobulins in Hodgkin's disease. Immunology (1967) 1.28
Polymerase chain reaction for detection of residual leukaemia. Lancet (1989) 1.28
Molecular epidemiology of two consecutive outbreaks of parainfluenza 3 in a bone marrow transplant unit. J Clin Microbiol (1998) 1.27
Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood (2000) 1.27
Consistent fusion of ZNF198 to the fibroblast growth factor receptor-1 in the t(8;13)(p11;q12) myeloproliferative syndrome. Blood (1998) 1.25
Homozygous deletions of the p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia. Blood (1995) 1.25
Kinetics of indium-III labelled lymphocytes in normal subjects and patients with Hodgkin's disease. Br Med J (1977) 1.24
Late-onset hemorrhagic cystitis associated with urinary excretion of polyomaviruses after bone marrow transplantation. Transplantation (1987) 1.23
British HIV Association guidelines for HIV-associated malignancies 2008. HIV Med (2008) 1.23
Pharmacokinetics of CAMPATH-1H in BMT patients. Cytotherapy (2001) 1.22
CCNU (lomustine), idarubicin and dexamethasone (CIDEX): an effective oral regimen for the treatment of refractory or relapsed myeloma. Br J Haematol (2000) 1.21
Phagocytic function of leucocytes from patients with acute myeloid and chronic granulocytic leukaemia. Br J Haematol (1973) 1.20
Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse. Leukemia (2005) 1.19
T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities. Blood (2000) 1.19
Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: correlations with acute graft-versus-host disease and relapse. Br J Haematol (1993) 1.18